The EANM guideline for radiosynoviorthesis

W.U. Kampen; B. Boddenberg-Paetzold; M. Fischer; M. Gabriel; R. Klett; M. Konijnenberg; E. Kresnik; H. Lellouche; F. Paycha; L. Terslev; C. Turkmen; F. van der Zant; L. Antunovic; E. Panagiotidis; G. Gnanasegaran; T. Kuwert; T. Van den Wyngaert

doi:10.1007/s00259-021-05541-7

The EANM guideline for radiosynoviorthesis

W.U. Kampen, B. Boddenberg-Paetzold, M. Fischer, M. Gabriel, R. Klett, M. Konijnenberg, E. Kresnik, H. Lellouche, F. Paycha, L. Terslev, C. Turkmen, F. van der Zant, L. Antunovic, E. Panagiotidis, G. Gnanasegaran, T. Kuwert^*, T. Van den Wyngaert

^*Corresponding author for this work

Radiology & Nuclear Medicine

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

1 Downloads (Pure)

Abstract

Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.

Original language	English
Pages (from-to)	681-708
Number of pages	28
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	49
Issue number	2
Early online date	20 Oct 2021
DOIs	https://doi.org/10.1007/s00259-021-05541-7
Publication status	Published - Jan 2022

Bibliographical note

Funding Information:
We thank the EANM Committees and the National Societies of Nuclear Medicine for the revision of this guideline. The comments and suggestions from the EANM Dosimetry Committee, the Oncology & Theranostics Committee, the Radiation Protection Committee, the Inflammation & Infection Committee, the Radiopharmacy Committee and the Technologist Committee, and the comments and suggestions from the Swedish, the Polish and the French Society of Nuclear Medicine, and the European League against Rheumatism (eular) are highly appreciated and have been considered for this guideline.

Publisher Copyright:
© 2021, The Author(s).

Access to Document

10.1007/s00259-021-05541-7Licence: CC BY

s00259-021-05541-7Final published version, 1.49 MBLicence: CC BY

Cite this

Kampen, W. U., Boddenberg-Paetzold, B., Fischer, M., Gabriel, M., Klett, R., Konijnenberg, M., Kresnik, E., Lellouche, H., Paycha, F., Terslev, L., Turkmen, C., van der Zant, F., Antunovic, L., Panagiotidis, E., Gnanasegaran, G., Kuwert, T., & Van den Wyngaert, T. (2022). The EANM guideline for radiosynoviorthesis. European Journal of Nuclear Medicine and Molecular Imaging, 49(2), 681-708. https://doi.org/10.1007/s00259-021-05541-7

@article{44f9cfc250c6450ab2d7aa57204383e2,

title = "The EANM guideline for radiosynoviorthesis",

abstract = "Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.",

author = "W.U. Kampen and B. Boddenberg-Paetzold and M. Fischer and M. Gabriel and R. Klett and M. Konijnenberg and E. Kresnik and H. Lellouche and F. Paycha and L. Terslev and C. Turkmen and {van der Zant}, F. and L. Antunovic and E. Panagiotidis and G. Gnanasegaran and T. Kuwert and {Van den Wyngaert}, T.",

note = "Funding Information: We thank the EANM Committees and the National Societies of Nuclear Medicine for the revision of this guideline. The comments and suggestions from the EANM Dosimetry Committee, the Oncology & Theranostics Committee, the Radiation Protection Committee, the Inflammation & Infection Committee, the Radiopharmacy Committee and the Technologist Committee, and the comments and suggestions from the Swedish, the Polish and the French Society of Nuclear Medicine, and the European League against Rheumatism (eular) are highly appreciated and have been considered for this guideline. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2022",

month = jan,

doi = "10.1007/s00259-021-05541-7",

language = "English",

volume = "49",

pages = "681--708",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer-Verlag",

number = "2",

}

Kampen, WU, Boddenberg-Paetzold, B, Fischer, M, Gabriel, M, Klett, R, Konijnenberg, M, Kresnik, E, Lellouche, H, Paycha, F, Terslev, L, Turkmen, C, van der Zant, F, Antunovic, L, Panagiotidis, E, Gnanasegaran, G, Kuwert, T & Van den Wyngaert, T 2022, 'The EANM guideline for radiosynoviorthesis', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 2, pp. 681-708. https://doi.org/10.1007/s00259-021-05541-7

TY - JOUR

T1 - The EANM guideline for radiosynoviorthesis

AU - Kampen, W.U.

AU - Boddenberg-Paetzold, B.

AU - Fischer, M.

AU - Gabriel, M.

AU - Klett, R.

AU - Konijnenberg, M.

AU - Kresnik, E.

AU - Lellouche, H.

AU - Paycha, F.

AU - Terslev, L.

AU - Turkmen, C.

AU - van der Zant, F.

AU - Antunovic, L.

AU - Panagiotidis, E.

AU - Gnanasegaran, G.

AU - Kuwert, T.

AU - Van den Wyngaert, T.

N1 - Funding Information: We thank the EANM Committees and the National Societies of Nuclear Medicine for the revision of this guideline. The comments and suggestions from the EANM Dosimetry Committee, the Oncology & Theranostics Committee, the Radiation Protection Committee, the Inflammation & Infection Committee, the Radiopharmacy Committee and the Technologist Committee, and the comments and suggestions from the Swedish, the Polish and the French Society of Nuclear Medicine, and the European League against Rheumatism (eular) are highly appreciated and have been considered for this guideline. Publisher Copyright: © 2021, The Author(s).

PY - 2022/1

Y1 - 2022/1

N2 - Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.

AB - Purpose Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in sclerosis and fibrosis of the formerly inflamed tissue, finally leading to reduced joint effusion and alleviation of joint pain.Methods The European Association of Nuclear Medicine (EANM) has written and approved these guidelines in tight collaboration with an international team of clinical experts, including rheumatologists. Besides clinical and procedural aspects, different national legislative issues, dosimetric considerations, possible complications, and side effects are addressed.Conclusion These guidelines will assist nuclear medicine physicians in performing radiosynoviorthesis. Since there are differences regarding the radiopharmaceuticals approved for RSO and the official indications between several European countries, this guideline can only give a framework that must be adopted individually.

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:000709301100001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1007/s00259-021-05541-7

DO - 10.1007/s00259-021-05541-7

M3 - Article

C2 - 34671820

VL - 49

SP - 681

EP - 708

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 2

ER -

The EANM guideline for radiosynoviorthesis

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this